Last reviewed · How we verify

Paracetamol-Tramadol — Competitive Intelligence Brief

Paracetamol-Tramadol (Paracetamol-Tramadol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Analgesic combination (non-opioid + opioid). Area: Pain Management.

marketed Analgesic combination (non-opioid + opioid) Cyclooxygenase (COX), opioid receptors (μ, δ, κ), norepinephrine transporter, serotonin transporter Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Paracetamol-Tramadol (Paracetamol-Tramadol) — Astes. This combination drug reduces pain through two complementary mechanisms: paracetamol inhibits prostaglandin synthesis in the central nervous system, while tramadol blocks monoamine reuptake and activates opioid receptors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Paracetamol-Tramadol TARGET Paracetamol-Tramadol Astes marketed Analgesic combination (non-opioid + opioid) Cyclooxygenase (COX), opioid receptors (μ, δ, κ), norepinephrine transporter, serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Analgesic combination (non-opioid + opioid) class)

  1. Astes · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paracetamol-Tramadol — Competitive Intelligence Brief. https://druglandscape.com/ci/paracetamol-tramadol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: